ClinicalTrials.gg
CompletedNCT04193761Updated Dec 10, 2019

TAURINE and HCC PATIENTS

An interventional study of taurine level in Taurine in HCC, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-10.

Sponsored by Ain Shams University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Mar 2017, registered Dec 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Study summary

Serum taurine level beside (AFP and AFU) are of great value in early diagnosis in HCC Egyptian patients and may have a rule in identifying end-stage liver disease (ESLD) patients candidate for LDLT.

Read the detailed description

Taurine has been demonstrated to have a direct and indirect antioxidant effect and to display antineoplastic activity by preventing angiogenesis and enhancing tumor cell apoptosis. Also it was suggested that measurement of serum taurine level in hepatic patients beside fibroscan is of great value in the early diagnosis of any fibrotic and cancerous liver changes.Aim of the work was to correlate serum taurine level with the levels of the specific tumor markers (α- fetoprotein and α-L-fucosidase ) for early diagnosis of different stages of HCC in Egyptian patients.

This observational case-control study was conducted in the Tropical Medicine Department, Ahmed Maher Teaching Hospital. Eighty hepatic patients were assigned to three groups (Chronic hepatitis, Cirrhosis and HCC). Twenty healthy subjects were enrolled as a control group. Serum levels of AFP, AFU, and taurine beside complete biochemical analysis and liver biopsies from all selected patients were done. Patients who accepted to be a candidate for living donor liver transplant (LDLT) were referred to Ain Shams University Specialized Hospital (ASUSH) liver transplant unit.

02

Conditions studied

  • Taurine in HCC
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,932 studies on the registry; 433 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic hepatitis
  • Cirrhosis
  • HCC patients

Exclusion criteria

Exclusion Criteria:

  • Patient refusal
  • Bleeding tendency
  • Tense ascites
  • Inability to obtain a liver biopsy
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Control

    Diagnostic Test: taurine level

  • Active comparator
    Chronic hepatitis

    Diagnostic Test: taurine level

  • Active comparator
    Cirrhosis

    Diagnostic Test: taurine level

  • Active comparator
    Hepatocellular carcinoma

    Diagnostic Test: taurine level

Interventions

  • Diagnostic testtaurine level

    Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.

06

What researchers measure

Primary outcomes

  1. Taurine level among patients groups

    Time frame: 8 months

07

Study locations

1 site
  • Hanaa El Gendy
    Cairo, Ain Shams University Specialized Hospital, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04193761
Responsible party
Hanaa Mohamed Abdallah ElGendy MD (Assistant Professor, Ain Shams University) — Principal investigator
First posted
Dec 10, 2019
Start date
Mar 17, 2017
Primary completion
Apr 20, 2018
Completion
Oct 25, 2018
Last update
Dec 10, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion